Your browser doesn't support javascript.
loading
Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma.
Przystal, Justyna M; Becker, Hannes; Canjuga, Denis; Tsiami, Foteini; Anderle, Nicole; Keller, Anna-Lena; Pohl, Anja; Ries, Carola H; Schmittnaegel, Martina; Korinetska, Nataliya; Koch, Marilin; Schittenhelm, Jens; Tatagiba, Marcos; Schmees, Christian; Beck, Susanne C; Tabatabai, Ghazaleh.
Afiliación
  • Przystal JM; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
  • Becker H; German Translational Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, 72076 Tübingen, Germany.
  • Canjuga D; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
  • Tsiami F; German Translational Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, 72076 Tübingen, Germany.
  • Anderle N; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
  • Keller AL; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
  • Pohl A; German Translational Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, 72076 Tübingen, Germany.
  • Ries CH; NMI, Natural and Medical Sciences Institute, University of Tübingen, 72770 Reutlingen, Germany.
  • Schmittnaegel M; NMI, Natural and Medical Sciences Institute, University of Tübingen, 72770 Reutlingen, Germany.
  • Korinetska N; NMI, Natural and Medical Sciences Institute, University of Tübingen, 72770 Reutlingen, Germany.
  • Koch M; Roche Innovation Center Munich, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Schittenhelm J; Roche Innovation Center Munich, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
  • Tatagiba M; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
  • Schmees C; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
  • Beck SC; German Translational Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, 72076 Tübingen, Germany.
  • Tabatabai G; Institute for Neuropathology, University Hospital Tübingen, 72076 Tübingen, Germany.
Cancers (Basel) ; 13(10)2021 May 15.
Article en En | MEDLINE | ID: mdl-34063518
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza